Dosage Related Efficacy and Tolerability of Cannabidiol in Children With Treatment-Resistant Epileptic Encephalopathy: Preliminary Results of the CARE-E Study

Despite the proven positive effect of cannabidiol in the treatment of children suffered severe forms of epilepsy, there is uncertainty about the appropriate dose of cannabidiol (CBD) for epilepsia nutans.

The resultant inability to provide evidence-based dosing and therapeutic monitoring of Cannabis-based products in children, combined with concerns regarding potential intoxicant effects of Δ9-tetrahydrocannabinol (THC), leads to a reluctance by many physicians to authorize CHE to these patients. Employees of the University of Saskatchewan in Canada conducted a study to determine the optimal dosage of drugs in the treatment of epilepsy in children. On the NCBI website the preliminary data of seven participants of the Cannabidiol application study in children with refractory epileptic encephalopathy (CARE-E) are presented.